Firstly, we investigated the effects of pharmacological CHK1 inhibition in four bladder cancer cell lines representing the heterogeneity of bladder cancer; thus, our findings cannot simply be extended to all bladder cancer cells. This evidence concerns the gene CHEK1 and urinary bladder cancer.